000112525 001__ 112525
000112525 005__ 20230519145617.0
000112525 0247_ $$2doi$$a10.1186/s12879-021-06821-1
000112525 0248_ $$2sideral$$a127524
000112525 037__ $$aART-2021-127524
000112525 041__ $$aeng
000112525 100__ $$aBendala Estrada, A.D.
000112525 245__ $$aInadequate use of antibiotics in the covid-19 era: effectiveness of antibiotic therapy
000112525 260__ $$c2021
000112525 5060_ $$aAccess copy available to the general public$$fUnrestricted
000112525 5203_ $$aBackground: Since December 2019, the COVID-19 pandemic has changed the concept of medicine. This work aims to analyze the use of antibiotics in patients admitted to the hospital due to SARS-CoV-2 infection. Methods: This work analyzes the use and effectiveness of antibiotics in hospitalized patients with COVID-19 based on data from the SEMI-COVID-19 registry, an initiative to generate knowledge about this disease using data from electronic medical records. Our primary endpoint was all-cause in-hospital mortality according to antibiotic use. The secondary endpoint was the effect of macrolides on mortality. Results: Of 13, 932 patients, antibiotics were used in 12, 238. The overall death rate was 20.7% and higher among those taking antibiotics (87.8%). Higher mortality was observed with use of all antibiotics (OR 1.40, 95% CI 1.21–1.62; p <.001) except macrolides, which had a higher survival rate (OR 0.70, 95% CI 0.64–0.76; p <.001). The decision to start antibiotics was influenced by presence of increased inflammatory markers and any kind of infiltrate on an x-ray. Patients receiving antibiotics required respiratory support and were transferred to intensive care units more often. Conclusions: Bacterial co-infection was uncommon among COVID-19 patients, yet use of antibiotics was high. There is insufficient evidence to support widespread use of empiric antibiotics in these patients. Most may not require empiric treatment and if they do, there is promising evidence regarding azithromycin as a potential COVID-19 treatment. © 2021, The Author(s).
000112525 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000112525 590__ $$a3.669$$b2021
000112525 592__ $$a1.042$$b2021
000112525 594__ $$a4.8$$b2021
000112525 591__ $$aINFECTIOUS DISEASES$$b60 / 96 = 0.625$$c2021$$dQ3$$eT2
000112525 593__ $$aInfectious Diseases$$c2021$$dQ2
000112525 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000112525 700__ $$aCalderón Parra, J.
000112525 700__ $$aFernández Carracedo, E.
000112525 700__ $$aMuiño Míguez, A.
000112525 700__ $$aRamos Martínez, A.
000112525 700__ $$aMuñez Rubio, E.
000112525 700__ $$aRubio-Rivas, M.
000112525 700__ $$aAgudo, P.
000112525 700__ $$aArnalich Fernández, F.
000112525 700__ $$aEstrada Perez, V.
000112525 700__ $$aTaboada Martínez, M.L.
000112525 700__ $$aCrestelo Vieitez, A.$$uUniversidad de Zaragoza
000112525 700__ $$aPesqueira Fontan, P.M.
000112525 700__ $$aBustamante, M.
000112525 700__ $$aFreire, S.J.
000112525 700__ $$aOriol-Bermúdez, I.
000112525 700__ $$aArtero, A.
000112525 700__ $$aOlalla Sierra, J.
000112525 700__ $$aAreses Manrique, M.
000112525 700__ $$aCarrasco-Sánchez, H.F.J.
000112525 700__ $$aVento, V.C.
000112525 700__ $$aGarcía García, G.M.
000112525 700__ $$aCubero-Morais, P.
000112525 700__ $$aCasas-Rojo, J.-M.
000112525 700__ $$aNúñez-Cortés, J.M.
000112525 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000112525 773__ $$g21 (2021), 1144 [23 pp.]$$pBMC INFECT DIS$$tBMC Infectious Diseases$$x1471-2334
000112525 8564_ $$s1227749$$uhttps://zaguan.unizar.es/record/112525/files/texto_completo.pdf$$yVersión publicada
000112525 8564_ $$s2511734$$uhttps://zaguan.unizar.es/record/112525/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000112525 909CO $$ooai:zaguan.unizar.es:112525$$particulos$$pdriver
000112525 951__ $$a2023-05-18-16:11:27
000112525 980__ $$aARTICLE